MECHANISMS OF RESISTANCE TO THE B-RAF INHIBITOR ZELBORAF IN FOUR MELANOMA CELL LINES

被引：0
|
作者：
Garg, E. [1 ]
Kong, X. [1 ]
Shi, H. [1 ]
Moriceau, G. [1 ]
Lo, R. S. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2012年 / 60卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [31] Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines
    Bloethner, S
    Chen, BW
    Hemminki, K
    Müller-Berghaus, J
    Ugurel, S
    Schadendorf, D
    Kumar, R
    CARCINOGENESIS, 2005, 26 (07) : 1224 - 1232
  • [32] Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
    Connor M. Blair
    Nicola M. Walsh
    Bruce H. Littman
    Frank W. Marcoux
    George S. Baillie
    BMC Cancer, 19
  • [33] VEMURAFENIB B-raf Kinase Inhibitor Oncolytic
    Puzanov, I.
    Flaherty, K. T.
    Sosman, J. A.
    Grippo, J. F.
    Su, F.
    Nolop, K.
    Lee, R. J.
    Bollag, G.
    DRUGS OF THE FUTURE, 2011, 36 (03) : 191 - 199
  • [34] The inability of Spry2 to inhibit B-Raf V600E activity is required for induction of resistance to B-Raf inhibitor in B-Raf V600E cells
    Han, Byeal-I
    Ahn, Jun-Ho
    Jang, Gun-Hee
    Kim, Na-Yeon
    Lee, Michael
    FASEB JOURNAL, 2015, 29
  • [35] Development of a novel inhibitor of cogenic b-raf
    Tsai, James
    Zhang, Jiazhong
    Bremer, Ryan
    Artis, Rick
    Hirth, Peter
    Bollag, Gideon
    CANCER RESEARCH, 2006, 66 (08)
  • [36] Overcoming kinase inhibitor resistance: EGFR, Bcr-Abl, and b-Raf
    Gray, Nathanael S.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [37] Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (01) : 205 - 206
  • [38] New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma
    Teuma, Cecile
    Perier-Muzet, Marie
    Pelletier, Solenne
    Nouvier, Mathilde
    Amini-Adl, Mona
    Dijoud, Frederique
    Duru, Gerard
    Thomas, Luc
    Fouque, Denis
    Laville, Maurice
    Dalle, Stephane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 419 - 426
  • [39] New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma
    Cécile Teuma
    Marie Perier-Muzet
    Solenne Pelletier
    Mathilde Nouvier
    Mona Amini-Adl
    Frédérique Dijoud
    Gérard Duru
    Luc Thomas
    Denis Fouque
    Maurice Laville
    Stéphane Dalle
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 419 - 426
  • [40] B-Raf: How One Mutation Leads to Melanoma
    Zhao, Hongru
    Choe, Jana
    Leng, Yunzhao
    Alex, Katherine
    FASEB JOURNAL, 2022, 36
12345